PPLPHARMA

Piramal Pharma Limited

Contract development and manufacturing, hospital generics and consumer healthcare business

Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals

piramal.com(opens the company website in a new tab)
Ask AI

Key metrics

Price as of 2026-10-16

Stock price
₹197.73
Market cap
26,246 Cr
Stock P/E
Loss (TTM EPS ₹-2.36)
P/B
3.21
Dividend yield
0.1%
ROE (FY26)
-4.0%
ROCE (FY26)
1.2%
Operating margin (FY26)
1.0%
Debt / equity (FY26)
0.67
OCF / EBITDA (FY26)
179.3%
OCF / EBITDA (3Y)
99.6%

Full years shown; sign in free for the trailing twelve months. Learn about these metrics →

Price & valuation

Share price and valuation multiples (P/E, P/B and more) over time.

Loading price history…

Compare with peers

Loading peers…

What you need to know

Piramal Pharma sells contract development and manufacturing (CDMO) services to big pharma and emerging biopharma customers, hospital injectable and anaesthesia products through its Complex Hospital Generics (CHG) business, and consumer healthcare brands in India through its Consumer Healthcare business.

Company snapshot

24thBy market cap

Ranked among 119 companies in Pharmaceuticals.

What we see

Positives
  • ✓100% of operating profit came in as cash over the last three years — profits are backed by real cash.
Concerns
  • ✗Net margin is negative — the company is spending more than it earns right now.
2 more signals from the filings.Sign in free to see them all

Statement tables · Consolidated

Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.

Amounts in ₹ Cr · tap + to expand rows

Quarterly results

Quarterly · ₹ Cr · tap + rows to expand

MetricSept 2023Dec 2023Mar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Sales1,911 Cr1,959 Cr2,552 Cr1,951 Cr2,242 Cr2,204 Cr2,754 Cr1,934 Cr2,044 Cr2,140 Cr2,752 Cr2,270 Cr
Operating expenses (approx.)1,646 Cr1,690 Cr2,022 Cr1,747 Cr1,900 Cr1,866 Cr2,193 Cr1,827 Cr1,885 Cr1,944 Cr2,291 Cr2,075 Cr
EBITDA266 Cr268 Cr530 Cr204 Cr342 Cr338 Cr561 Cr107 Cr159 Cr196 Cr461 Cr195 Cr
OPM %13.9%13.7%20.8%10.5%15.2%15.3%20.4%5.5%7.8%9.1%16.7%8.6%
Other income49 Cr62 Cr26 Cr20 Cr61 Cr12 Cr42 Cr58 Cr66 Cr43 Cr46 Cr89 Cr
Interest110 Cr106 Cr114 Cr107 Cr108 Cr103 Cr104 Cr86 Cr82 Cr89 Cr83 Cr88 Cr
Depreciation185 Cr186 Cr196 Cr185 Cr192 Cr197 Cr243 Cr197 Cr203 Cr213 Cr218 Cr224 Cr
Profit before tax40 Cr19 Cr227 Cr-45 Cr120 Cr67 Cr273 Cr-79 Cr-46 Cr-94 Cr43 Cr-7 Cr
Tax %87.3%47.8%55.5%-96.6%81.2%94.5%43.7%-3.4%-114.9%-45.1%120.5%-830.2%
Net profit5 Cr10 Cr101 Cr-89 Cr23 Cr4 Cr154 Cr-82 Cr-99 Cr-136 Cr-9 Cr-69 Cr
EPS (₹)₹0.04₹0.08₹0.77₹-0.67₹0.17₹0.03₹1.16₹-0.62₹-0.75₹-1.03₹-0.07₹-0.52

Profit & loss (annual)

Annual · last column is TTM · ₹ Cr · tap + to expand

MetricMar 2023Mar 2024Mar 2025Mar 2026TTM
Sales7,082 Cr8,171 Cr9,151 Cr8,869 CrSign in free for the trailing twelve months
Operating expenses (approx.)6,453 Cr6,975 Cr7,706 Cr7,947 CrSign in free for the trailing twelve months
EBITDA628 Cr1,196 Cr1,445 Cr922 CrSign in free for the trailing twelve months
OPM %8.9%14.6%15.8%10.4%Sign in free for the trailing twelve months
Other income225 Cr175 Cr135 Cr213 CrSign in free for the trailing twelve months
Interest344 Cr448 Cr422 Cr341 CrSign in free for the trailing twelve months
Depreciation677 Cr741 Cr816 Cr831 CrSign in free for the trailing twelve months
Profit before tax-120 Cr179 Cr415 Cr-176 CrSign in free for the trailing twelve months
Tax %-55.2%90.1%78.0%-85.1%Sign in free for the trailing twelve months
Net profit-186 Cr18 Cr91 Cr-326 CrSign in free for the trailing twelve months
EPS (₹)₹-1.57₹0.14₹0.69₹-2.46Sign in free for the trailing twelve months
Dividend payout %—0.0%15.9%—Sign in free for the trailing twelve months
Sign in free for the trailing twelve months

The latest four quarters added up, next to each full year

Balance sheet

Annual · ₹ Cr · tap + rows to expand

MetricMar 2023Mar 2024Mar 2025Mar 2026
Equity capital1,193 Cr1,323 Cr1,324 Cr1,327 Cr
Reserves5,580 Cr6,588 Cr6,801 Cr6,835 Cr
Borrowings5,505 Cr4,559 Cr4,720 Cr5,495 Cr
Other liabilities2,244 Cr2,842 Cr2,832 Cr4,307 Cr
Total liabilities14,523 Cr15,312 Cr15,678 Cr17,965 Cr
Fixed assets (net)3,363 Cr3,873 Cr4,176 Cr4,451 Cr
CWIP853 Cr566 Cr489 Cr799 Cr
Investments639 Cr385 Cr291 Cr437 Cr
Inventories1,681 Cr2,176 Cr2,313 Cr3,064 Cr
Trade receivables1,799 Cr2,134 Cr2,350 Cr2,158 Cr
Cash & bank196 Cr357 Cr369 Cr1,200 Cr
Other assets5,991 Cr5,821 Cr5,691 Cr5,856 Cr
Total assets14,523 Cr15,312 Cr15,678 Cr17,965 Cr

Cash flows

Annual · ₹ Cr · tap + rows to expand · last column includes FCF

MetricMar 2023Mar 2024Mar 2025Mar 2026
Cash from operating activity484 Cr1,005 Cr892 Cr1,653 Cr
Cash from investing-1,339 Cr-434 Cr-477 Cr-826 Cr
Cash from financing818 Cr-422 Cr-441 Cr-39 Cr
Net cash flow-32 Cr166 Cr-37 Cr794 Cr
Free cash flow (OCF − Capex)-481 Cr293 Cr228 Cr763 Cr

Ratios

MetricMar 2023Mar 2024Mar 2025Mar 2026
ROCE %1.8%5.0%6.5%1.2%
ROE %-2.8%0.2%1.1%-4.0%
Debtor days92959389
Inventory days364402409559
Days payable258284272452
Cash conversion cycle198213231195
OCF / EBITDA %77.0%84.0%61.8%179.3%
OCF / EBITDA % (3 years)——72.8%99.6%
Debt / equity0.810.580.580.67
Current ratio1.261.251.541.51
Net debt / EBITDA8.453.513.014.66